Epigenetic regulators are attractive targets for the development of new cancer therapies. Among them, the ATP-dependent chromatin remodeling complexes control the chromatin architecture and have important roles in gene regulation. They are often found to be mutated and de-regulated in cancers, but how they influence the cancer gene expression program during cancer initiation and progression is not fully understood. Here we show that the INO80 chromatin remodeling complex is required for oncogenic transcription and tumor growth in non-small-cell lung cancer (NSCLC). Ino80, the SWI/SNF ATPase in the complex, is highly expressed in NSCLC cells compared with normal lung epithelia cells. Further, its expression, as well as that of another subunit Ino80B, negatively correlates with disease prognosis in lung cancer patients. Functionally, INO80 silencing inhibits NSCLC cell proliferation and anchorage-independent growth in vitro and tumor formation in mouse xenografts. It occupies enhancer regions near lung cancer-associated genes, and its occupancy correlates with increased genome accessibility and enhanced expression of downstream genes. Together, our study defines a critical role of INO80 in promoting oncogenic transcription and NSCLC tumorigenesis, and reveals a potential treatment strategy for inhibiting the cancer transcription network by targeting the INO80 chromatin remodeling complex.
INTRODUCTION
Despite advances in diagnosis and therapy, lung cancer is still the leading cause of cancer mortality throughout the world. 1, 2 It is often diagnosed at advanced or metastatic stage and the existing therapies can only provide limited benefit. Therefore, it remains a critical and immediate goal for lung cancer research to understand the disease and develop more-effective treatments.
Non-small-cell lung cancer (NSCLC) represents more than 85% of all lung cancer cases. 3 Technical improvements in highthroughput sequencing and advances from fields such as epigenetics and developmental biology have provided insights into the molecular mechanisms of lung cancer and facilitated the development of targeted therapies. 4, 5 For example, the identification of driver mutations in signaling pathways, such as EGFR, ALK, KRAS, as the primary oncogenic events in some NSCLCs led to a revolutionary change in the diagnosis and treatments of the disease. These targeted treatments offered a significant improvement of outcomes and disease prognosis in target populations. However, drug resistance inevitably develops after initial remission. In addition, the treatments show limited efficacy in nontargeted populations. Therefore, further investigations in lung cancer mechanisms and new therapeutic strategies are of significant scientific and social values.
Besides genetic mutations, epigenetic alterations such as aberrant DNA methylation, histone modification or chromatin regulation, are also widely involved in tumorigenesis. 6, 7 Not surprisingly, epigenetic regulators have critical roles in cancer development. 8, 9 Among epigenetic factors, the ATP-dependent chromatin remodeling complexes have the ability to alter nucleosome composition and position to influence chromatin architecture and gene expression. 10, 11 By controlling the packing and unpacking of the chromatin, chromatin remodelers provide regulated DNA accessibility and have instructive roles in cell fate decision during cancer development and progression. Indeed, some chromatin remodelers show an unexpectedly high mutation rate, and the mutations may result in impaired higher-order genome structure and gene regulation. [12] [13] [14] However, the true significance of chromatin remodelers in tumorigenesis and tumor progression remains to be fully elucidated.
ATP-dependent chromatin remodelers can be divided into four families based on domain structures and subunit compositions, including SWI/SNF, ISWI, CHD and INO80. [15] [16] [17] Recent studies showed that inactivating mutations in the subunits of the SWI/SNF family chromatin remodelers are associated in various human cancers, suggesting that the SWI/SNF remodelers mostly act as tumor suppressors. [12] [13] [14] In comparison, the involvement of the other remodeling complex families in cancer is not well characterized. Here we show that the INO80 chromatin remodeling complex promotes oncogenic transcription and tumor growth in lung cancer. Our study reveals a critical role of INO80 in lung cancer tumorigenesis and suggests a novel strategy for cancer treatment by targeting oncogenic transcription.
RESULTS

INO80 expression is up-regulated in lung cancer
Our previous study indicates that INO80 is required for embryonic stem cell self-renewal by selectively activating pluripotency genes. 18 Because genes and pathways important for ESC maintenance are often re-activated in cancer, [19] [20] [21] and because other chromatin remodelers have been implicated in tumorigenesis, [12] [13] [14] we hypothesize that INO80 may also have an important role in cancer. To test the hypothesis, we first examined the alteration frequency of the INO80 subunits in various cancers based on the The Cancer Genome Atlas (TCGA) data (http://cancergenome.nih.gov/). We found that INO80 subunits show high alteration frequency in many cancer types. Although different subunits are differentially altered (Supplementary Figure S1) , collectively INO80 complex is frequently found in lung cancers, with up to 50% of cases harboring amplifications in at least one subunit (Figure 1a) . Furthermore, Kaplan-Meier survival analysis showed that patients with lower expression of the INO80 subunits Ino80 or Ino80B have significantly higher probability of survival (Figure 1b) . These results suggest that INO80 expression positively correlates with lung cancer development. To provide further evidence, we examined the expression the SWI/SNF ATPase in the complex, Ino80, in human lung cancer cell lines. By western blot, we found that Ino80 expression is upregulated in several NSCLC cell lines (A549, H23, H358, H1299, H1703) compared with the normal human bronchial epithelial cells NHBE and normal human bronchial epithelial cell line BEAS-2B (Figure 1c ). Taken together, these results strongly support our hypothesis that INO80 has an important role in NSCLC. Figure S2A) . More importantly, Ino80 silencing significantly reduced cancer cell proliferation and/or viability as shown by the growth curves (Figure 2a) . In order to minimize the off-target effect, we designed and tested additional shRNAs against Ino80. All the Ino80 shRNAs produced similar results in gene silencing as well as growth suppression in lung cancer cells (Supplementary Figures S2B and C) . In comparison, Ino80 silencing did not impair the growth and/or survival of the control NHBE or BEAS-2B cells (Supplementary Figure S2D) .
Next, we tested whether INO80 is required for the clonogenicity and anchorage-independent growth of the cancer cells, as these assays are commonly used as indicators of the tumorigenicity of transformed or cancerous cells. We found that Ino80 silencing in the A549, H1703, H358, H23 and H1299 NSCLC lines markedly inhibited colony formation in monolayer culture and anchorageindependent growth in soft-agar (Supplementary Figures S2B-E and S3). Finally, to investigate the role of INO80 in NSCLC growth in vivo, we tested the requirement for Ino80 in a mouse xenograft model. We transduced A549, H1299 and H1703 cells with lentivirus expressing either the control-or Ino80-shRNA, and injected the cells subcutaneously into immunocompromised animals. Although control-shRNA-transduced cells continued to grow and form tumors in the injected animals, Ino80-shRNA transduced cells show significant reduction in tumor growth, as measured by both tumor size and/or mass 4 weeks after injection ( Figure 3) . Collectively, the above data indicate that INO80 has an essential role in NSCLC tumorigenesis.
INO80 promotes the expression of lung cancer-associated genes To understand how INO80 regulates lung cancer development, we first examined gene expression changes caused by Ino80 silencing in A549 by RNA-seq. Ino80 silencing led to differential expression of 1759 genes, with 1112 genes showing reduced expression and 647 genes showing increased expression. As there were significantly more genes being downregulated (P o 0.0001), we hypothesized that INO80 may normally promote the expression of these genes ( Figure 4a ). Interestingly, we noticed that many known lung cancer-associated genes such as CTNNB1, 22 Cxcl5, 23 Map3k1, 24 Sec62 25 and Znf703, 26 were downregulated after Ino80 depletion ( Figure 4b ). Therefore, we carried out Ingenuity pathway analysis on the 1112 downregulated genes, and found that indeed they were highly enriched for genes involved in cancer (Figure 4c ). In addition, ingenuity upstream regulator analysis 27 showed that the gene expression changes caused by Ino80 silencing resemble those caused by the perturbations of Kras, Myc, Pik3ca and Erbb2 ( Figure 4d ). As many of these predicted upstream regulators have been previously implicated in lung cancers, 28, 29 this result suggested that INO80 and lung cancer genes may impinge on similar downstream targets during cancer development. Together, our data support the notion that INO80 promotes the expression of lung cancer-associated genes.
To test whether INO80 directly regulates these cancerassociated genes, we carried out chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) using Ino80 as the bait. We identified 7126 Ino80-bound peaks in A549 lung cancer cells, which were assigned to 5605 nearest genes. These Ino80-bound genes include those known lung cancer-associated genes CTNNB1, Cxcl5, Map3k1, Sec62 and Znf703, as confirmed by ChIP-qPCR ( Figure 5a ). Furthermore, ingenuity pathway analysis showed that Ino80-bound genes are highly enriched for those involved in cancer (Figure 5b ). Between the 5605 INO80-occupied genes and the 1759 differentially expressed genes after Ino80 silencing, 580 were in common and are likely direct targets of INO80 ( Figure 5c ). Again, these 580 potential INO80 targets are highly enriched for genes involved in cancer development ( Figure 5d ). Together, the above results suggest that INO80 may activate the expression of lung cancer-associated genes to promote lung cancer tumorigenesis.
INO80 occupies enhancers near lung cancer-associated genes To understand how INO80 regulates gene expression, we compared the genomic occupancy of Ino80 and histone markers. We found that the Ino80 peaks were enriched in gene-rich chromosomal regions and were often found near transcription start sites (Figure 6a ). Further, Ino80 binding strongly correlated with those of active enhancer markers, including H3K4me1, H3K27ac and p300 (Figure 6b ). In contrast, Ino80 bound regions show minimal occupancy by the repressive marker H3K27me3. Interestingly, gene set enrichment analysis (GSEA) indicated that genes near Ino80-bound enhancers are highly enriched for those that show elevated expression in in A549 (Figure 6c ). Therefore, these results suggest that INO80 occupies enhancers near cancerassociated genes. To investigate the functional consequence of INO80 occupancy, we examined the impact of Ino80 silencing on those cancer-associated genes whose enhancers are occupied by INO80. Compared with all genes, the cancer-associated genes with Ino80 occupancy showed more significant downregulation after Ino80 silencing (Figure 6d ), suggesting that INO80 normally activates the enhancers and promotes downstream gene expression.
It has been reported that INO80 catalyzes the removal of unacetylated H2A.Z from chromatin to facilitate gene transcription in yeast. 30 Furthermore, acetylation of histone H3 on lysine 56 (H3K56ac) enhances the H2A.Z replacement activity of INO80. 31 Thus, we carried out H2A.Z and H3K56ac ChIP-seq in A549 cells transduced with non-targeting or Ino80 shRNA viruses. We found that Ino80 silencing did not drastically change H2A.Z or H3K56ac occupancy at Ino80-bound promoter regions (Supplementary Figure S4) , suggesting that H3K56ac modification or H2A.Z eviction may not account for the gene expression changes caused by Ino80 silencing in A549.
Finally, because INO80 is a chromatin remodeler, we hypothesized that it may regulate gene expression by regulating chromatin structure and genome accessibility. To test the hypothesis, we compared Ino80 occupancy to a published data set of DNase I hypersensitivity sites in A549 cells. DNase I hypersensitive sites are genomic regions that are sensitive to nuclease cleavage, and are often used as indicators of open chromatin regions. We found that there is a strong overlap between INO80-bound regions and DNase I hypersensitive sites (Figure 6e ). Furthermore, INO80-bound regions showed significantly higher DNase I sensitivity compared with INO80-unbound regions (Figure 6f ). Collectively, our data support the following model: in lung cancer, INO80 occupies enhancers near cancerassociated genes. Its binding leads to a more open chromatin state and enhanced genome accessibility, thereby activating oncogenic transcription to promote tumorigenesis (Figure 6g ).
DISCUSSION
Originally discovered in yeast, the INO80 chromatin remodeling complex has been implicated in transcription regulation, DNA replication and repair, and embryonic stem cell maintenance. [15] [16] [17] However, unlike the SWI/SNF family remodeler, its involvement in cancer was not well understood. In this study, we show that INO80 is required for lung cancer cell growth in vitro and tumor formation in mouse xenografts. We propose that INO80 binds enhancer regions near cancer-associated genes and promotes their expression by increasing genome accessibility. Our study uncovered a novel function of INO80 in cancer development, and revealed a critical role of chromatin remodeling in the regulation of enhancers and oncogenic transcription.
It has been suggested that the activity of certain molecular pathways in ESCs and cancers may be closely related, as the acquired ability of cancer cells to divide perpetually and support tumor growth resembles that of ESCs. Indeed, genes that are essential for ESC self-renewal are often found to have important roles in cancer, [19] [20] [21] and the gene expression signature and higher-order chromatin structure show some resemblance between ESCs and cancers. 32 As INO80 also regulates the ESC state, our results on INO80 in NSCLC add additional support to these earlier findings. Further, it is possible that INO80 may contribute to the potential parallels in the regulation of the chromatin state in ESCs and cancer cells.
Chromatin remodeling complexes use the energy of ATP hydrolysis to modulate nucleosome composition and positioning. They can regulate the chromatin structure and accessibility of genomic regions where they reside to influence the binding of transcription factors or transcription machineries, and thereby control gene expression. 10, 11 We found that INO80 occupies enhancer regions near cancer-associated genes. Furthermore, its occupancy strongly correlates with increased DNase I hypersensitivity. These results suggested that INO80 may facilitate the establishment and/or maintenance of an open chromatin state at enhancers to promote the expression of downstream genes.
Our findings are consistent with previous reports that chromatin remodeling regulates enhancer activities. 33, 34 Interestingly, Ino80 depletion was reported to inhibit proliferation and anchorageindependent growth of oncogene-transformed mouse embryonic fibroblasts. However, Ino80 haploinsufficiency did not change tumor incidence and latency in p53 deletion mice. 35 It is possible that Ino80 expression in the heterozygote mice is still high enough to allow tumorigenesis, and different cancers or different cell types may show different dependency on the expression level of Ino80.
In recent years, it has become increasingly obvious that understanding the epigenetic regulations in lung cancer development may open new avenues for clinical intervention. [7] [8] [9] Compared with genetic alterations, epigenetic modifications are usually reversible. Moreover, they often simultaneously impact multiple genes and pathways essential for cancer cell survival and proliferation. Thus, targeting epigenetic mechanisms in cancer can provide unique opportunities for the development of more effective therapeutic strategies. Among epigenetic changes, chromatin remodeling is critical to the modulation of gene expression across a variety of physiological processes including cancer. [12] [13] [14] Growing evidence indicates that chromatin remodeling complexes have a widespread role in tumorigenesis. However, most chromatin remodelers studied so far typically show loss-offunction mutations in cancers and are not directly targetable. In comparison, we found that INO80 promotes oncogenic transcription and tumorigenesis. Indeed, amplifications of INO80 subunits mass (c, e, g ). Data were plotted as mean ± s.e.m., and n = 8 in each group. P-value was calculated by two-tailed Student's t-test.
were widely found in various cancers including lung cancer, and correlated with poor disease prognosis. Therefore, our findings suggest a potential new strategy for cancer treatment by inhibiting the INO80-dependent oncogenic transcription.
MATERIALS AND METHODS
Cell culture A549, H1703, H358, H23 and H1299 cell lines were obtained from ATCC, and cultured in DMEM supplemented with 10% fetal bovine serum (FBS). Normal lung bronchial epithelial cells NHBE and cell line BEAS-2B was from Lonza (Basel, Switzerland), and was cultured using the BEGM BulletKit (Lonza).
For lentiviral shRNA infections, cells were plated at~1 × 10 5 per well in 12-well plates. On the next day, shRNA lentiviruses were added to the cells, with fresh medium and polybrene at 5 μg/ml. The plate was centrifuged at 1000 g for 45 min at room temperature, and cells were returned to the incubator and cultured.
For growth curves, cells were transduced with either shNT or shIno80 lentiviruses, and subsequently re-plated in 24-well plates. Cell number was counted at the indicated time points. Growth curves were generated from the average of three experiments, and plotted as mean ± s.e.m.
For clonogenic assays, cells were plated in triplicate at appropriate cell densities for each cell line (100-500 cells per well) in six-well plates, and cultured for 2-4 weeks for colony formation. Resulting colonies were washed once with phosphate-buffered saline (PBS), fixed and stained with 0.05% (w/v) crystal violet in 50% methanol and 10% acetic acid for 30 min at room temperature. Colonies were carefully rinsed with distilled water, until background staining of the wells was minimal. Plates were air-dried and scanned. Staining intensities were quantified with ImageJ (https:// imagej.nih.gov/ij/).
For anchorage-independent growth in soft agar, cells were resuspended in 0.4% agar in complete medium at 1 × 10 4 per well in six-well plates and layered on top of 0.6% agar as described previously. After 14 days, colonies were stained with 2 mg/ml MTT dissolved in PBS, for 1 h at 37 ℃. Plates were scanned and colonies were quantified with ImageJ.
Mouse xenografts
All animal experiments were conducted following protocols approved by the Animal Care and Use Committee of the National Institute of Environmental Health Sciences. A549 cells were infected with shNT or shIno80 lentiviruses. Two days later, 2 × 10 6 cells in 0.1 ml of PBS were injected subcutaneously into 6-week-old male SCID-BEIGE mice (Charles River Laboratories, Wilmington, MA, USA). Injected mice were divided into the shNT and shIno80 groups and mixed randomly within each group. Five weeks after injection, mice were killed without blinding and tumors formed from the injection sites were removed for analysis.
Western blot
Cells were lysed in cell lysis buffer (Thermo Scientific, Waltham, MA, USA) containing the protease inhibitor cocktail (Roche, Basel, Switzerland). The lysates were sonicated and quantified by BCA assay (Life Technologies, Carlsbad, CA, USA). Forty micrograms of total protein was loaded and separated by SDS-PAGE on 4-12% Bis-Tris gel (Life Technologies) and transferred to nitrocellulose membranes. The membranes were blocked by Table S3 for the complete list.
5% milk in TBS-T and then incubated with Ino80 antibody (Proteintech, Rosemont, IL, USA, 18810-1-AP) overnight at 4 ℃. Afterwards, membranes were incubated with secondary antibodies and developed using ECL Detection Kit (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA).
RNA isolation, RT-qPCR and RNA-seq Total RNA was isolated from cells using the GeneJet RNA purification kit (Thermo Scientific), and 0.5 μg total RNA was reverse transcribed to generate cDNA using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) according to manufacturer's instructions. qPCRs were performed using the SsoFast EvaGreen Supermix (Bio-Rad) on the Bio-Rad CFX-384 or CFX-96 real-time PCR System. Actin was used for normalization. Primers used in the study are listed in Supplementary Table S1 .
For RNA-seq, 1 μg total RNA was used for sequencing library generation using the Truseq RNA Library Prep Kit V2 (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. All libraries were sequenced on the NextSeq sequencer (Illumina) using the 75 nt paired-end sequencing protocol. All sequencing data have been deposited to the GEO database with the accession number: GSE85119. ChIP-qPCR and ChIP-Seq sample preparation Ino80 ChIP were performed as described previously. Briefly, A375 or SK-MEL-147 cells were fixed using 1% formaldehyde for 10 min, and 0.125 M glycine was added to stop the fixation. Cells were harvested, and DNA was fragmented to 300-500 bp by sonication with a micro-tip attached to a Misonix 3000 sonicator. Immunoprecipitation was performed with Ino80 antibody (Proteintech 18810-1-AP) conjugated to Dynabeads protein G beads (Life Technologies). ChIP DNA was eluted, reverse cross-linked, extracted by phenol/chloroform, and precipitated. For ChIP-seq, 1 ng ChIP DNA or input DNA was used to generate sequencing libraries using the Nextera XT DNA sample preparation Kit (Illumina). Libraries were sequenced on the NextSeq sequencer (Illumina) using the 75 nt pairedend sequencing protocol. All sequencing data will be deposited to the GEO database and made available to the public.
TCGA data analysis TCGA data were processed as previously described. 36 In brief, TCGA mRNA expression data were obtained from TCGA Synapse portal (syn300013). We obtained patient overall survival time from TCGA marker papers, or TCGA data portal (https://gdc.cancer.gov/). We used the univariate Cox test to examine whether the expression level was significantly correlated with patient survival (if you used Cox P-value). We divided the patients into two groups based on their gene expression values (cutoff as median expression value), and then used logrank test to examine whether the expression level was significantly correlated with patient survival and displayed it in KaplanMeier Survival curves (if you used KM P-value).
RNA-Seq analysis
Raw reads were filtered to only include those with a mean Phred quality score of 20 or greater. Adapter was trimmed from the reads using Trim Galore version 0.2.8. The filtered reads were aligned to the hg19 assembly using Tophat2 version 2.0.4. For the alignment and all subsequent analyses that require a gene model, a RefSeq gene model downloaded from the UCSC browser on 5 February 2013 was used. To get raw read counts for each gene, the htseq-count tool in the HTSeq package version 0.6.0 was used. The read counts were normalized and differentially expressed genes (DEGs) were identified using the DESeq R package version 1.14. 
ENCODE ChIP-Seq data
For all analyses of H3K4me3, H3K4me1, H3K27ac, p300, H3K27me3 and DNase I, publically available ENCODE ChIP-Seq data were downloaded from the UCSC browser. Please see Supplementary Table S6 for data sets used for the analysis.
ChIP-Seq analysis
Adapter was removed using Cutadapt version 1.2.1. Reads were filtered to only include those with a mean Phred quality score of 20 or greater. The filtered reads were aligned to the hg19 assembly using Bowtie version 0.12.8 with the following paramters: -v 2 -m 1 --best --strata -I 15 -X 1000. The aligned reads were deduplicated by removing any read pairs where both mates aligned to the same genomic positions as another read. To obtain genome coverage tracks, the genomecov tool from the BEDTools suite version 2.17.0 was used. To normalize the coverage, the density was multiplied by 10 million and divided by the number of aligned, deduplicated read pairs. To call peaks, SICER version 1.1 was used, with the following paramters: REDUNDANCY_THRESHOLD = 100, WINDOW_-SIZE = 200, GAP_SIZE = 800, SPECIES = hg19, EFFECTIVE_GENOME_FRAC-TION = 0.77, FDR = 0.00001. The peaks were categorized as a TSS peak if it overlapped with a RefSeq TSS, or a gene body peak if it did not overlap with a TSS but did overlap with a RefSeq gene body. If it did not overlap with either, then it was categorized as intergenic. The RefSeq gene model used for this categorization and all subsequent analyses that require a gene model was downloaded from the UCSC browser on 5 February 2013. Ino80-bound genes were identified by finding the closest RefSeq TSS to each Ino80 peak center. Peaks were only included if it had a fold change in signal compared to input of 2 or greater, and if the TSS was within 20 kb of the peak center. Heatmaps were generated by calculating the average normalized ChIP-seq signal in 100 nt bins in the region 5 kb upstream and downstream of the Ino80 peak centers. The rows were sorted by the FDR values associated with the peaks. The DNase I metagene was created by first generating a heatmap of the average normalized DNase I signal in 100 nt bins in the region 5 kb upstream and downstream of all RefSeq TSSs. Then, the genes in the heatmap were split into two categories, based on whether or not the TSS overlapped with an Ino80 peak. Finally, the metagenes were generated by taking the average of the genes within each category for all bins. Ino80-bound enhancer peaks were defined as Ino80 peaks with a fold change over input of 2 or greater that also overlap with an H3K4me1 peak and an H3K27ac peak and a p300 peak. Ino80-bound enhancer genes were defined based on the closest TSS to the Ino80-bound enhancer peaks.
Microarray analysis
Publically available microarray expression data from A549 cells and normal lung cells were downloaded from GEO (accession numbers GSM185869 and GSM185872). To obtain a single expression measurement for each gene, the average of all probes associated with a given gene was calculated. GSEA analysis was performed using the GseaPreranked tool in GSEA version 2.1.0 on the log2 fold change between the A549 cells and normal lung. Ino80-bound targets used for the boxplot were defined as any Ino80-bound enhancer genes that were also upregulated with a fold change of 2 or greater between the A549 cells and normal lung. The P-value for the difference between all genes and Ino80-bound targets was calculated using a two-sample Student's t-test.
